Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
G610487-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $310.90 | |
G610487-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,060.90 |
Synonyms | Galidesivir|249503-25-1|IMMUCILLIN A|Immucillin-A|BCX4430|BCX-4430|BCX 4430 Free Base|(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol|OLF97F86A7|BCX4430 freebase|ImmA cpd|3,4-Pyrrolidinediol,2-(4-Amino-5h-Py |
---|---|
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Replicase polyprotein 1ab inhibitor |
ALogP | -2.1 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol |
---|---|
INCHI | InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1 |
InChi Key | AMFDITJFBUXZQN-KUBHLMPHSA-N |
Canonical SMILES | C1=C(C2=C(N1)C(=NC=N2)N)C3C(C(C(N3)CO)O)O |
Isomeric SMILES | C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O |
Alternate CAS | 249503-25-1 |
PubChem CID | 10445549 |
MeSH Entry Terms | 2-(4-amino-5H-pyrrolo(3,2-d)pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol;BCX-4430;BCX4430;Galidesivir;ImmA cpd;immucillin A;immucillin-A |
Molecular Weight | 265.27 |
PubChem CID | 10445549 |
---|---|
CAS Registry No. | 249503-25-1 |
ChEMBL Ligand | CHEMBL1236524 |
BindingDB Ligand | 50513995 |
DrugBank Ligand | DB11676 |
RCSB PDB Ligand | UA2 |
Enter Lot Number to search for COA:
1. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G et al.. (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.. Nature, 508 (7496): (402-5). [PMID:24590073] |
2. Bernatchez JA, Tran LT, Li J, Luan Y, Siqueira-Neto JL, Li R. (2020) Drugs for the Treatment of Zika Virus Infection.. J Med Chem, 63 (2): (470-489). [PMID:31549836] |
3. Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X et al.. (2020) Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.. Antiviral Res, 178 (3): (104786). [PMID:32251767] |